USRE37003E - Pharmaceutical composition for inhibiting the growth of cancers - Google Patents

Pharmaceutical composition for inhibiting the growth of cancers Download PDF

Info

Publication number
USRE37003E
USRE37003E US09/368,685 US36868599A USRE37003E US RE37003 E USRE37003 E US RE37003E US 36868599 A US36868599 A US 36868599A US RE37003 E USRE37003 E US RE37003E
Authority
US
United States
Prior art keywords
unit dosage
bis
triazolyl
dosage composition
propanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/368,685
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to US09/368,685 priority Critical patent/USRE37003E/en
Application granted granted Critical
Publication of USRE37003E publication Critical patent/USRE37003E/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals.
  • the composition contains a 1,3-bis-triazolyl-2-propanol derivative.
  • Cancers are the leading cause of death in animals and humans.
  • the exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.
  • chemotherapeutic agents Many types have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells. The exact mechanism for the action of these chemotherapeutic agents are not always known.
  • cytocidal or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing.
  • hormones in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylating agents, and anti-metabolites form the bulk of therapies available to oncologists.
  • cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable.
  • an object of this invention to provide an anti-cancer composition
  • a pharmaceutical carrier and a 1,3-bis-triazolyl-2-propanol derivative as defined herein along with a method for treating such cancers.
  • a pharmaceutical composition for treatment of mammals, and in particular, warm blooded animals and humans comprising a pharmaceutical carrier and an effective amount anti-cancer compound selected from the group consisting of: ##STR1## wherein R 1 is an optionally substituted alkyl, cycloalkyl (e.g. cyclopentyl or cyclohexyl), aryl or haloaryl (e.g. phenyl or 2,4-dichlorophenyl) or aralkyl (e.g., benzyl); and salts and metal complexes and ethers or esters thereof, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
  • cycloalkyl e.g. cyclopentyl or cyclohexyl
  • aryl or haloaryl e.g. phenyl or 2,4-dichlorophenyl
  • aralkyl e.g., benzyl
  • compositions can be used to inhibit the growth of cancers, leukemia and other tumors in humans or animals by administration of an effective amount either orally, rectally, topically or parenterally, intravenously or by injection into the tumor. These compositions do not significantly affect healthy cells as compared to adriamycin which has a detrimental effect on healthy cells.
  • compositions are also effective against viruses. Therefore it is an object of this invention to provide a composition effective against HIV, herpes, influenza, rhinoviruses and the like.
  • the term “comprising” means various components can be conjointly employed in the pharmaceutical composition of this invention. Accordingly, the tenms “consisting essentially of” and “consisting of” are embodied in the term comprising.
  • a "pharmaceutically acceptable” component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
  • safe and effective amount refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
  • the specific "safe and effective amount” will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
  • a "pharmaceutical addition salts” is salt of the anti-cancer compound with an organic or inorganic acid.
  • These preferred acid addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.
  • a "pharmaceutical carrier” is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human.
  • the carrier may be liquid or solid and is selected with the planned manner of administration in mind.
  • cancer refers to all types of cancers or neoplasm or malignant tumors, including leukemia, found in mammals.
  • anti-cancer compounds are the 1,3-bis-triazolyl-2-propanols, and their salts.
  • the exact 1,3-bis-triazolyl-2-propanols are described in detail below.
  • the preferred materials are the products sold under the names "fluconazole®” by Pfizer.
  • virus includes viruses which cause diseases (viral infection) in man and other warm blooded animals such as HIV virus, herpes, influenza and rhinoviruses.
  • the anti-cancer compounds are 1,3-bis-triazolyl-2-propanol derivatives which are known for their antifungal activities. They are systemic fungicides used to prevent and eradicate fungi.
  • the compounds have the following structure: ##STR2## wherein R 1 is an optionally substituted alkyl, cycloalkyl (e.g. cyclopentyl or cyclohexyl), aryl or haloaryl (e.g. phenyl or 2,4-dichlorophenyl) or aralkyl (e.g., benzyl); and salts and metal complexes and ethers or esters thereof, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
  • cycloalkyl e.g. cyclopentyl or cyclohexyl
  • aryl or haloaryl e.g. phenyl or 2,4-dichlorophenyl
  • such bis triazole derivatives as 2-(2,4-dichloropheyl)-1,3-bis(1H-1,2, 4-triazole-1-yl)propan-2-ol and its corresponding 2- and 4-chlorophenyl analogs and 2,4-diflourophenyl analogs are useful herein.
  • the composition is 2-(2,4-difluorophenyl)-1,3-bis (1H-1,2,4-triazol-1-yl)propan-2-ol and its pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
  • any suitable dosage may be given in the method of the invention.
  • the type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor, virus, cancer or disease being treated. Generally a dosage of betRween about 2 milligrams (mg) per kilogram (kg) of body weight and about 400 mg per kg of body weight is suitable. Preferably from 15 mg to about 150 mg/kg of body weight is used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice.
  • a dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds.
  • the dosage unit can also comprise diluents, extenders, carriers and the like.
  • the unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration or injection into or around the tumor.
  • the anti-cancer compounds are typically mixed with a pharmaceutically acceptable carrier.
  • This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used.
  • the active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form.
  • suitable solid carriers include lactose, sucrose, gelatin and agar.
  • Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
  • liquid dosage forms examples include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
  • Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents.
  • Oral dosage forms optionally contain flavorants and coloring agents.
  • Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.
  • the method of treatment can be any suitable method which is effective in the treatment of the particular cancer or tumor type or virus that is being treated.
  • Treatment may be oral, rectal, topical, parenteral or intravenous administration or by injection into the tumor and the like.
  • the method of applying an effective amount also varies depending on the tumor being treated. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the 1,3-triazolyl-2-propanol compounds, formulated with an appropriate carrier, additional cancer inhibiting compound or compounds or diluent to facilitate application will be the preferred method of administering the compounds to warm blooded animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals comprising fungicide is disclosed. The particular fungicide used is a 1,3-bis-triazolyl-2-propanol derivative. These compositions are also effective against viral infections.

Description

This is a continuation of application Ser. No. 08/473,818, filed on Jun. 7, 1995 U.S. Pat. No. 5,665,751.
TECHNICAL FIELD
This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a 1,3-bis-triazolyl-2-propanol derivative.
BACKGROUND OF THE INVENTION
Cancers are the leading cause of death in animals and humans. The exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.
Many types of chemotherapeutic agents have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells. The exact mechanism for the action of these chemotherapeutic agents are not always known.
Despite advances in the field of cancer treatment the leading therapies to date are surgery, radiation and chemotherapy. Chemotherapeutic approaches are said to fight cancers that are metastasized or ones that are particularly aggressive. Such cytocidal or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing. To date, hormones, in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylating agents, and anti-metabolites form the bulk of therapies available to oncologists. Ideally cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable. Unfortunately, none have been found and instead agents which target especially rapidly dividing cells (both tumor and normal) have been used.
Clearly, the development of materials that would target tumor cells due to some unique specificity for them would be a breakthrough. Alternatively, materials that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable. Therefore, it is an object of this invention to provide a pharmaceutical composition that is effective in inhibiting the growth of tumors and cancers in mammals with mild or no effects on normal cells.
More specifically, it is an object of this invention to provide an anti-cancer composition comprising a pharmaceutical carrier and a 1,3-bis-triazolyl-2-propanol derivative as defined herein along with a method for treating such cancers.
These and other objects will become evident from the following detailed description of this inventions.
SUMMARY OF THE INVENTION
A pharmaceutical composition for treatment of mammals, and in particular, warm blooded animals and humans, comprising a pharmaceutical carrier and an effective amount anti-cancer compound selected from the group consisting of: ##STR1## wherein R1 is an optionally substituted alkyl, cycloalkyl (e.g. cyclopentyl or cyclohexyl), aryl or haloaryl (e.g. phenyl or 2,4-dichlorophenyl) or aralkyl (e.g., benzyl); and salts and metal complexes and ethers or esters thereof, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids. Specifically, such bis triazole derivatives as 2-2,4-dichlorophenyl)-1,3-bis(1H-1, 2,4-triazole-1-yl)propan-2-ol and its corresponding 2- and 4-chlorophenyl analogs and 2,4-diflourophenyl analogs are claimed.
These compositions can be used to inhibit the growth of cancers, leukemia and other tumors in humans or animals by administration of an effective amount either orally, rectally, topically or parenterally, intravenously or by injection into the tumor. These compositions do not significantly affect healthy cells as compared to adriamycin which has a detrimental effect on healthy cells.
These compositions are also effective against viruses. Therefore it is an object of this invention to provide a composition effective against HIV, herpes, influenza, rhinoviruses and the like.
DETAILED DESCRIPTION OF THE INVENTION A. DEFINITIONS
As used herein, the term "comprising" means various components can be conjointly employed in the pharmaceutical composition of this invention. Accordingly, the tenms "consisting essentially of" and "consisting of" are embodied in the term comprising.
As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
As used herein, a "pharmaceutical addition salts" is salt of the anti-cancer compound with an organic or inorganic acid. These preferred acid addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.
As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.
As used herein, "cancer" refers to all types of cancers or neoplasm or malignant tumors, including leukemia, found in mammals.
As used herein, the "anti-cancer compounds" are the 1,3-bis-triazolyl-2-propanols, and their salts. The exact 1,3-bis-triazolyl-2-propanols are described in detail below. The preferred materials are the products sold under the names "fluconazole®" by Pfizer.
As used herein, "viruses" includes viruses which cause diseases (viral infection) in man and other warm blooded animals such as HIV virus, herpes, influenza and rhinoviruses.
B. THE ANTI-CANCER COMPOUNDS
The anti-cancer compounds are 1,3-bis-triazolyl-2-propanol derivatives which are known for their antifungal activities. They are systemic fungicides used to prevent and eradicate fungi. The compounds have the following structure: ##STR2## wherein R1 is an optionally substituted alkyl, cycloalkyl (e.g. cyclopentyl or cyclohexyl), aryl or haloaryl (e.g. phenyl or 2,4-dichlorophenyl) or aralkyl (e.g., benzyl); and salts and metal complexes and ethers or esters thereof, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids. Specifically, such bis triazole derivatives as 2-(2,4-dichloropheyl)-1,3-bis(1H-1,2, 4-triazole-1-yl)propan-2-ol and its corresponding 2- and 4-chlorophenyl analogs and 2,4-diflourophenyl analogs are useful herein. Preferably the composition is 2-(2,4-difluorophenyl)-1,3-bis (1H-1,2,4-triazol-1-yl)propan-2-ol and its pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
These compounds are prepared according to the method described in U.S. Pat. No. 4,404,216 issued to Richardson, Sep. 13, 1983 and British Patent Application No. 2,078, 719A published Jan. 13, 1982 and European patent application No. 44,605 published Jan. 27, 1982 (both assigned to Imperial Chemical Industries Ltd).
It is believed that these particular fungicides have the capability of reducing tumors or decreasing their growth significantly because of their ability to inhabit the synthesis of sterols.
C. DOSAGE
Any suitable dosage may be given in the method of the invention. The type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor, virus, cancer or disease being treated. Generally a dosage of betRween about 2 milligrams (mg) per kilogram (kg) of body weight and about 400 mg per kg of body weight is suitable. Preferably from 15 mg to about 150 mg/kg of body weight is used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. The dosage unit can also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration or injection into or around the tumor.
D. DOSAGE DELIVERY FORMS
The anti-cancer compounds are typically mixed with a pharmaceutically acceptable carrier. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. The active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents. Oral dosage forms optionally contain flavorants and coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.
Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in U.S. Pat. No. 3,903,297 to Robert, issued Sep. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, IntroiRdtReon to Pharmaceutical Dosage Forms 2nd Edition (1976).
E. METHOD OF TREATMENT
The method of treatment can be any suitable method which is effective in the treatment of the particular cancer or tumor type or virus that is being treated. Treatment may be oral, rectal, topical, parenteral or intravenous administration or by injection into the tumor and the like. The method of applying an effective amount also varies depending on the tumor being treated. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the 1,3-triazolyl-2-propanol compounds, formulated with an appropriate carrier, additional cancer inhibiting compound or compounds or diluent to facilitate application will be the preferred method of administering the compounds to warm blooded animals.

Claims (11)

What is claimed is:
1. A unit dosage composition for treating cancer in animals or humans comprising .[.from about 150 mg/kg to.]. about 400 mg/kg of a 1,3-bis-triazolyl-2-propanol of the formula: ##STR3## wherein R1 is an optionally substituted allyl, cycloalkyl, aryl or haloaryl or aralkyl (e.g., benzyl); and salts and metal complexes and ethers or esters thereof and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
2. A unit dosage composition according to claim 1 wherein said 1,3-bis-triazolyl-2-propanol is selected from the group consisting of 2-2,4-dichloropheyl)-1,3-bis(1H-1, 2,4-triazole-1-yl)propan-2-ol and its corresponding 2- and 4-chlorophenyl analogs and 2,4-diflourophenyl analogs.
3. A unit dosage composition according to claim 2 wherein said pharmaceutical acceptable acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof. .[.4. A unit dosage composition according to claim 3 comprising from about 150 mg/kg body
weight to about 400 mg/kg of said 1,3-bis-triazolyl-2-propanol..].5. A unit dosage composition according to claim .[.4.]. .Iadd.3 .Iaddend.wherein said 1,3-bis-triazolyl-2-propanol is for oral or enteric
or intravenous, peritoneal administration. 6. A unit dosage composition according to claim .[.4.]. .Iadd.3 .Iaddend.comprising said
1,3-bis-triazolyl-2-propanol in a solid form. 7. A unit dosage composition according to claim 6 wherein said solid form includes a carrier selected from the group consisting of lactose, sucrose, gelatin and agar. .[.8. A unit dosage composition according to claim 7 comprising about 400 mg/kg of
said 1,3-bis-triazolyl-2-propanol..].9. A unit dosage composition according to claim .[.8.]. .Iadd.15 .Iaddend.wherein said liquid dosage .[.from.]. .Iadd.form .Iaddend.is selected from the group consisting of aqueous solutions, emulsions, suspension solutions, and suspensions
reconstituted from non-effervescent and effervescent preparations. 10. A unit dosage composition according to claim 9 wherein said liquid dosage .[.form a member.]. .Iadd.form is .Iaddend.selected from the group consisting of suspending agents, diluents, sweeteners, flavorants, colorants, preservatives, emulsifying agents and coloring agents, and
mixtures thereof. 11. A unit dosage composition for treating viral infections in animals or humans comprising .[.from about 150 mg/kg body weight to.]. about 400 mg/kg a 1,3-bis-triazolyl-2-propanol of the formula: ##STR4## wherein R1 is an optionally substituted alkyl, cycloalkyl, aryl or haloaryl or aralkyl; and salts and metal complexes and ethers or esters thereof and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids. .[.12. A unit dosage composition according to claim 11 comprising about 400 mg/kg of body weight of said
1,3-bis-triazolyl-2-propanol..].13. A unit dosage composition according to claim 11 comprising said 1,3-bis-triazolyl-2-propanol in a solid form.
A unit dosage composition according to claim 11 comprising said 1,3-bis-triazolyl-2-propanol in a liquid form. .Iadd.15. A unit dosage composition accrrding to claim 3 comprising said 1,3-bis-triazolyl-2-propanol in liquid form..Iaddend.
US09/368,685 1995-06-07 1999-08-05 Pharmaceutical composition for inhibiting the growth of cancers Expired - Fee Related USRE37003E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/368,685 USRE37003E (en) 1995-06-07 1999-08-05 Pharmaceutical composition for inhibiting the growth of cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,818 US5665751A (en) 1995-06-07 1995-06-07 Pharmaceutical composition for inhibiting the growth of cancers
US08/911,171 US5840742A (en) 1995-06-07 1997-08-14 Pharmaceutical composition for inhibiting the growth of cancers
US09/368,685 USRE37003E (en) 1995-06-07 1999-08-05 Pharmaceutical composition for inhibiting the growth of cancers

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US08/473,818 Continuation US5665751A (en) 1995-06-07 1995-06-07 Pharmaceutical composition for inhibiting the growth of cancers
US08/911,171 Reissue US5840742A (en) 1995-06-07 1997-08-14 Pharmaceutical composition for inhibiting the growth of cancers

Publications (1)

Publication Number Publication Date
USRE37003E true USRE37003E (en) 2000-12-26

Family

ID=23881116

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/473,818 Expired - Fee Related US5665751A (en) 1995-06-07 1995-06-07 Pharmaceutical composition for inhibiting the growth of cancers
US08/911,171 Ceased US5840742A (en) 1995-06-07 1997-08-14 Pharmaceutical composition for inhibiting the growth of cancers
US09/368,685 Expired - Fee Related USRE37003E (en) 1995-06-07 1999-08-05 Pharmaceutical composition for inhibiting the growth of cancers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/473,818 Expired - Fee Related US5665751A (en) 1995-06-07 1995-06-07 Pharmaceutical composition for inhibiting the growth of cancers
US08/911,171 Ceased US5840742A (en) 1995-06-07 1997-08-14 Pharmaceutical composition for inhibiting the growth of cancers

Country Status (20)

Country Link
US (3) US5665751A (en)
EP (1) EP0831815A1 (en)
JP (1) JPH11506733A (en)
KR (1) KR19990022618A (en)
CN (1) CN1259867A (en)
AR (1) AR003430A1 (en)
AU (1) AU717201B2 (en)
BR (1) BR9609093A (en)
CA (1) CA2223803A1 (en)
CZ (1) CZ391897A3 (en)
HU (1) HUP9802629A3 (en)
IL (1) IL118426A (en)
NO (1) NO975661L (en)
NZ (1) NZ308393A (en)
PL (1) PL324078A1 (en)
SK (1) SK168797A3 (en)
TR (2) TR199701535T1 (en)
TW (1) TW466113B (en)
WO (1) WO1996040120A1 (en)
ZA (1) ZA964377B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US20030032664A1 (en) * 1999-08-13 2003-02-13 The Procter & Gamble Company Method of cancer treatment
US20040029942A1 (en) * 2000-09-26 2004-02-12 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of viral infections
US6720349B2 (en) 2000-09-26 2004-04-13 Uaf Technologies And Research, Llc Compounds for use in the treatment of cancer or viral infections
US20050119236A1 (en) * 1997-05-16 2005-06-02 University Of Arizona Foundation Cancer treatments and pharmaceutical compositions therefor
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286758B6 (en) * 1994-03-21 2000-06-14 Thomsen John Brown Pharmaceutical preparation in the form of a gel for treating skin diseases
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
NZ503921A (en) * 1995-08-04 2002-03-01 Procter & Gamble Use of fluconazole mixed with chemotherapeutic agents for inhibiting the growth of cancers or tumors
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6515074B2 (en) * 2001-01-22 2003-02-04 Delphi Technologies, Inc. Thermoplastic polymer alloy compositions and process for manufacture thereof
CN100334084C (en) * 2005-04-26 2007-08-29 武汉大学 Bi-triazole compound, preparation method and application thereof
CN100451007C (en) * 2006-10-12 2009-01-14 杭州宇龙化工有限公司 compound containing aromatic ether and ditriazole and use thereof
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
US8536113B2 (en) 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
KR100980328B1 (en) * 2007-12-14 2010-09-06 한국생명공학연구원 Composition for prevention or treatment of cancer containing triazolyl-thio-ethanone derivatives or pharmaceutically acceptable salts thereof inhibiting protein phosphatase as an active ingredient
CN102321036A (en) * 2011-07-13 2012-01-18 王健祥 Preparation method of fluconazole soluble salt

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079062A (en) * 1974-11-18 1978-03-14 Janssen Pharmaceutica N.V. Triazole derivatives
US4160838A (en) * 1977-06-02 1979-07-10 Janssen Pharmaceutica N.V. Antimicrobial and plant-growth-regulating triazole derivatives
GB2078719A (en) * 1980-06-02 1982-01-13 Ici Ltd Heterocyclic compounds
US4404216A (en) * 1981-06-06 1983-09-13 Pfizer Inc. Antifungal 1,3-bis-triazolyl-2-propanol derivative
US5126359A (en) * 1988-11-04 1992-06-30 Bayer Aktiengesellschaft Substituted bisazoles and their use as medicaments
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5360612A (en) * 1992-10-13 1994-11-01 Pfizer Inc. Pharmaceutical compositions containing triazole derivatives for rectal administration

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079062A (en) * 1974-11-18 1978-03-14 Janssen Pharmaceutica N.V. Triazole derivatives
US4160838A (en) * 1977-06-02 1979-07-10 Janssen Pharmaceutica N.V. Antimicrobial and plant-growth-regulating triazole derivatives
GB2078719A (en) * 1980-06-02 1982-01-13 Ici Ltd Heterocyclic compounds
EP0044605A1 (en) * 1980-06-02 1982-01-27 Imperial Chemical Industries Plc Fungicidal bis-azolyl compounds
US4404216A (en) * 1981-06-06 1983-09-13 Pfizer Inc. Antifungal 1,3-bis-triazolyl-2-propanol derivative
US5126359A (en) * 1988-11-04 1992-06-30 Bayer Aktiengesellschaft Substituted bisazoles and their use as medicaments
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5360612A (en) * 1992-10-13 1994-11-01 Pfizer Inc. Pharmaceutical compositions containing triazole derivatives for rectal administration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Benzaquen et al, Nature Medicine, vol. 1, No. 6, Jun. 1995. *
Copending application of Camden, serial No. 08/674,182, filed Jul. 16, 1996 claiming priority to provisional application No. 60/001,836 and copending application serial No. 473,819,180 filed Jun. 7, 1995, copending application serial No. 08/673,819. *
Physicians Desk Reference, 1535:33, Diflucan, Medical Economics Data Productions Co, Montvale, NJ., 1995. *
Schwartz et al, Inhibition of all trans retinoic acid metabolism by Fluconazole in vitro and in Patients with Acute Promyelocytic Leukemia, Biochem. Pharmacol., vol. 50, No. 7, pp. 923 928, Sep. 1995. *
Schwartz et al, Inhibition of all trans-retinoic acid metabolism by Fluconazole in vitro and in Patients with Acute Promyelocytic Leukemia, Biochem. Pharmacol., vol. 50, No. 7, pp. 923-928, Sep. 1995.

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6653335B2 (en) 1995-04-12 2003-11-25 University Of Arizona Foundationa Pharmaceutical composition for inhibiting the growth of viruses and cancers
US20050119236A1 (en) * 1997-05-16 2005-06-02 University Of Arizona Foundation Cancer treatments and pharmaceutical compositions therefor
US20050192328A1 (en) * 1997-05-16 2005-09-01 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections
US20050288349A1 (en) * 1997-05-16 2005-12-29 Uaf Technologies And Research, Llc Cancer treatments and pharmaceutical compositions therefor
US6984654B2 (en) 1997-05-16 2006-01-10 Uaf Technologies And Research, Llc Cancer treatments and pharmaceutical compositions therefor
US20030032664A1 (en) * 1999-08-13 2003-02-13 The Procter & Gamble Company Method of cancer treatment
US6906091B2 (en) 1999-08-13 2005-06-14 Uaf Technologies And Research, Llc Method of cancer treatment
US20040029942A1 (en) * 2000-09-26 2004-02-12 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of viral infections
US6720349B2 (en) 2000-09-26 2004-04-13 Uaf Technologies And Research, Llc Compounds for use in the treatment of cancer or viral infections
US6916836B2 (en) 2000-09-26 2005-07-12 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections

Also Published As

Publication number Publication date
TR200102287T2 (en) 2002-06-21
AR003430A1 (en) 1998-08-05
JPH11506733A (en) 1999-06-15
PL324078A1 (en) 1998-05-11
NO975661D0 (en) 1997-12-05
NO975661L (en) 1998-02-09
CA2223803A1 (en) 1996-12-19
KR19990022618A (en) 1999-03-25
NZ308393A (en) 2001-04-27
AU717201B2 (en) 2000-03-23
IL118426A0 (en) 1996-09-12
CZ391897A3 (en) 1998-05-13
AU5802196A (en) 1996-12-30
BR9609093A (en) 1999-06-29
SK168797A3 (en) 1998-12-02
TW466113B (en) 2001-12-01
CN1259867A (en) 2000-07-12
HUP9802629A2 (en) 1999-04-28
IL118426A (en) 2001-03-19
HUP9802629A3 (en) 2000-01-28
US5840742A (en) 1998-11-24
ZA964377B (en) 1997-02-17
TR199701535T1 (en) 1998-03-21
US5665751A (en) 1997-09-09
EP0831815A1 (en) 1998-04-01
WO1996040120A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
USRE37003E (en) Pharmaceutical composition for inhibiting the growth of cancers
US5880144A (en) Pharmaceutical composition for inhibiting the growth of viruses and cancers comprising thiabendazole
US6228876B1 (en) Pharmaceutical composition for inhibiting the growth of cancers
US5665713A (en) Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
EP0820281B1 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses
US5629341A (en) Pharmaceutical composition for inhibiting the growth of viruses and cancers
AU717382B2 (en) Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
US6110953A (en) Pharmaceutical composition for inhibiting the growth of cancers
MXPA97007809A (en) A pharmaceutical composition containing benzymidazole to inhibit the growth of cance
MXPA97009530A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicinal product for the treatment of cance
MXPA97009833A (en) Use of benzimidazoles for the manufacture of a medicine for the treatment of leuce
MXPA97009712A (en) Use of 1,2,4-triazol derivatives for the manufacturing of a medicine for the treatment of cance

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

LAPS Lapse for failure to pay maintenance fees